Age-related macular degeneration (ARMD) – Related resources
- Interferon alfa-2a appears not to be beneficial for the treatment of age-related macular degeneration and may even have harmful effects [Evidence Level: B].
- Vitamin E or beta-carotene supplements will not prevent or delay the onset of age-related macular degeneration [Evidence Level: A].
- There is insufficient evidence on the benefits and harms of steroids with antiangiogenic properties for treating neovascular age-related macular degeneration [Evidence Level: D].
- Surgical removal of choroidal neovascularisation in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration does not prevent visual loss compared to observation, and the risk of developing cataract and retinal detachment increases after surgery [Evidence Level: A].
- Laser photocoagulation of drusen appears no to reduce the risk of developing choroidal neovascularisation, geographic atrophy, or visual acuity loss [Evidence Level: B].
- Statins seem to have no effect on the onset or progression of age-related macular degeneration, although the evidence is insufficient [Evidence Level: D].
- Coleman HR, Chan CC, Ferris FL 3rd, Chew EY. Age-related macular degeneration. Lancet 2008 Nov 22;372(9652):1835-45. [PMID:19027484]
- Folk JC, Stone EM. Ranibizumab therapy for neovascular age-related macular degeneration. N Engl J Med 2010 Oct 21;363(17):1648-55. [PMID:20961248]
Copyright © 2017 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.